US 12,419,849 B2
Reagents, compositions and methods for improving viability and function of cells, tissues and organs
Shant Der Sarkissian, Laval (CA); and Nicolas Noiseux, Montreal (CA)
Assigned to TARGA BIOMEDICAL INC., Montreal (CA)
Filed by TARGA BIOMEDICAL INC., Montreal (CA)
Filed on Jul. 21, 2022, as Appl. No. 17/870,476.
Application 17/870,476 is a continuation of application No. 16/309,474, granted, now 11,446,265, previously published as PCT/CA2017/000151, filed on Jun. 15, 2017.
Claims priority of provisional application 62/350,258, filed on Jun. 15, 2016.
Prior Publication US 2023/0024103 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/19 (2006.01); A01N 1/125 (2025.01); A01N 1/126 (2025.01); A01N 1/128 (2025.01); A61K 31/16 (2006.01); A61K 31/164 (2006.01); A61P 9/10 (2006.01)
CPC A61K 31/19 (2013.01) [A01N 1/125 (2025.01); A01N 1/126 (2025.01); A01N 1/128 (2025.01); A61K 31/16 (2013.01); A61K 31/164 (2013.01); A61P 9/10 (2018.01)] 34 Claims
OG exemplary drawing
 
1. An in vitro or ex vivo method of modulating the state of a cell, a cell preparation, a tissue, a graft or an organ so as to increase resistance to hypoxia reoxygenation stress
the method comprising:
contacting the cell, the cell preparation, the tissue, the graft or the organ with:
a) a composition comprising one or more of the following compounds:

OG Complex Work Unit Chemistry
or
a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof,
b) a secretome of: a distinct cell preparation that has been contacted with a composition comprising the one or more of the Analog 1, the Analog 2, the Analog 3, and the Analog 4, or a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof or with the combination thereof,
wherein the cell or cell preparation is non-cancerous.